DGI:Ambulant erworbene Pneumonie/Quellen: Difference between revisions

From Infektiopedia
imported>Bestem
No edit summary
imported>Bestem
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
*Hochspringen↑ Moore, M., et al., Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study. Eur Respir J, 2017. 50(5).
1. Almirall J, Bolíbar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004;125(4):1335-1342. doi:[https://doi.org/10.1378/chest.125.4.1335 10.1378/chest.125.4.1335]
*Hochspringen↑ Bauer, T.T., et al., CRB-65 predicts death from community-acquired pneumonia. J Intern Med, 2006. 260(1): p. 93-101.
*Hochspringen↑ Kolditz, M., et al., Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med, 2015. 278(2): p. 193-202.
*Hochspringen↑ Fine, M.J., et al., A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med, 1997. 336(4): p. 243-50.
*Hochspringen↑ Liapikou, A., et al., Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis, 2009. 48(4): p. 377-85.
*Hochspringen↑ Chalmers, J.D., et al., Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis, 2011. 53(6): p. 503-11.
*Hochspringen↑<nowiki>https://iqtig.org/downloads/berichte/2018/IQTIG_Qualitaetsreport-2019_2019-09-25.pdf</nowiki>, IQTIQ. Qualitätsreport. 2019.
*Hochspringen↑ Almirall, J., et al., Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest, 2004. 125(4): p. 1335-42.
*Hochspringen↑ Muller, F., et al., Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest, 2010. 138(1): p. 121-9.
*↑ Hochspringen nach:10,0 10,1 de With K, W.K., Kern WV et al S3-Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus. . 2018.
*Hochspringen↑ Forst, G., et al., Clinimetric properties and suitability of selected quality indicators for assessing antibiotic use in hospitalized adults: a multicentre point prevalence study in 24 hospitals in Germany. J Antimicrob Chemother, 2019. 74(12): p. 3596-3602.
*Hochspringen↑ Schuetz, P., et al., Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis, 2018. 18(1): p. 95-107.
*Hochspringen↑ <nowiki>https://link.springer.com/content/pdf/10.1007%2Fs00103-020-03123-w.pdf</nowiki>.
*Hochspringen↑ Torres, A., et al., Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease.Thorax, 2015. 70(10): p. 984-9.
*Hochspringen↑ Jensen, A.V., et al., Undiagnosed Diabetes Mellitus in Community-Acquired Pneumonia: A Prospective Cohort Study.Clin Infect Dis, 2017. 65(12): p. 2091-2098.


<br />
2. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T, CAPNETZ Study Group. CRB-65 predicts death from community-acquired pneumonia. J Intern Med. 2006;260(1):93-101. doi:[https://doi.org/10.1111/j.1365-2796.2006.01657.x 10.1111/j.1365-2796.2006.01657.x]


3. Chalmers JD, Taylor JK, Mandal P, et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis. 2011;53(6):503-511. doi:[https://doi.org/10.1093/cid/cir463 10.1093/cid/cir463]


4. Dinh A, Ropers J, Duran C, et al. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet. 2021;397(10280):1195-1203. doi:[https://doi.org/10.1016/S0140-6736(21)00313-5 10.1016/S0140-6736(21)00313-5]


1. Bader FG, Schröder M, Kujath P, Muhl E, Bruch H-P, Eckmann C. Diffuse postoperative peritonitis -- value of diagnostic parameters and impact of early indication for relaparotomy. Eur J Med Res. 2009;14(11):491-496. doi:10.1186/2047-783x-14-11-491
5. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250. doi:[https://doi.org/10.1056/NEJM199701233360402 10.1056/NEJM199701233360402]


2. Blot S, Antonelli M, Arvaniti K, et al. Epidemiology of intra-abdominal infection and sepsis in critically ill patients: “AbSeS”, a multinational observational cohort study and ESICM Trials Group Project. Intensive Care Med. 2019;45(12):1703-1717. doi:10.1007/s00134-019-05819-3
6. Först G, Kern WV, Weber N, et al. Clinimetric properties and suitability of selected quality indicators for assessing antibiotic use in hospitalized adults: a multicentre point prevalence study in 24 hospitals in Germany. J Antimicrob Chemother. 2019;74(12):3596-3602. doi:[https://doi.org/10.1093/jac/dkz364 10.1093/jac/dkz364]


3. Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs. 2005;65(12):1611-1620. doi:10.2165/00003495-200565120-00002
7. Jensen AV, Faurholt-Jepsen D, Egelund GB, et al. Undiagnosed Diabetes Mellitus in Community-Acquired Pneumonia: A Prospective Cohort Study. Clin Infect Dis. 2017;65(12):2091-2098. doi:[https://doi.org/10.1093/cid/cix703 10.1093/cid/cix703]


4. Blot S, De Waele JJ, Vogelaers D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs. 2012;72(6):e17-32. doi:10.2165/11599800-000000000-00000
8. Kolditz M, Ewig S, Schütte H, et al. Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med. 2015;278(2):193-202. doi:[https://doi.org/10.1111/joim.12349 10.1111/joim.12349]


5. Bodmann K-F, und die Expertenkommission der Infektliga. [Complicated intra-abdominal infections: pathogens, resistance. Recommendations of the Infectliga on antbiotic therapy]. Chirurg. 2010;81(1):38-49. doi:10.1007/s00104-009-1822-9
9. Laws H-J, Baumann U, Bogdan C, et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsbl. 2020;63(5):588-644. doi:[https://doi.org/10.1007/s00103-020-03123-w 10.1007/s00103-020-03123-w]


6. Bosscha K, Reijnders K, Hulstaert PF, Algra A, van der Werken C. Prognostic scoring systems to predict outcome in peritonitis and intra-abdominal sepsis. Br J Surg. 1997;84(11):1532-1534.
10. Liapikou A, Ferrer M, Polverino E, et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis. 2009;48(4):377-385. doi:[https://doi.org/10.1086/596307 10.1086/596307]


7. Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18 Suppl 7:19-37. doi:10.1111/1469-0691.12039
11. Moore M, Stuart B, Little P, et al. Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study. Eur Respir J. 2017;50(5):1700434. doi:[https://doi.org/10.1183/13993003.00434-2017 10.1183/13993003.00434-2017]


8. Cuenca-Estrella M, Verweij PE, Arendrup MC, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect. 2012;18 Suppl 7:9-18. doi:10.1111/1469-0691.12038
12. Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest. 2010;138(1):121-129. doi:[https://doi.org/10.1378/chest.09-2920 10.1378/chest.09-2920]


9. Eckmann C. [Antibiotic therapy of intra-abdominal infections in the era of multiresistance]. Chirurg. 2016;87(1):26-33. doi:10.1007/s00104-015-0106-9
13. Nagata N, Nikaido Y, Kido M, Ishibashi T, Sueishi K. Terminal pulmonary infections in patients with lung cancer. Chest. 1993;103(6):1739-1742. doi:[https://doi.org/10.1378/chest.103.6.1739 10.1378/chest.103.6.1739]


10. Laws H-J, Baumann U, Bogdan C, et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsbl. 2020;63(5):588-644. doi:10.1007/s00103-020-03123-w
14. Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95-107. doi:[https://doi.org/10.1016/S1473-3099(17)30592-3 10.1016/S1473-3099(17)30592-3]


11. León C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34(3):730-737. doi:10.1097/01.CCM.0000202208.37364.7D
15. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984-989. doi:[https://doi.org/10.1136/thoraxjnl-2015-206780 10.1136/thoraxjnl-2015-206780]


12. Montravers P, Leroy O, Eckmann C. Intra-abdominal candidiasis: it’s still a long way to get unquestionable data. Intensive Care Med. 2015;41(9):1682-1684. doi:10.1007/s00134-015-3894-y
16. Valvani A, Martin A, Devarajan A, Chandy D. Postobstructive pneumonia in lung cancer. Ann Transl Med. 2019;7(15):357. doi:[https://doi.org/10.21037/atm.2019.05.26 10.21037/atm.2019.05.26]


13. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220(6):751-758. doi:10.1097/00000658-199412000-00008
17. Qualitätsreport 2019. Published online 2019:246.


14. Ruhnke M, Rickerts V, Cornely OA, et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses. 2011;54(4):279-310. doi:10.1111/j.1439-0507.2011.02040.x
18. 092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf. Accessed July 9, 2021. <nowiki>https://www.awmf.org/uploads/tx_szleitlinien/092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf</nowiki>
 
15. Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2017;12:29. doi:10.1186/s13017-017-0141-6
 
16. Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162
 
17. 092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf. Accessed August 9, 2021. <nowiki>https://www.awmf.org/uploads/tx_szleitlinien/092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf</nowiki>

Latest revision as of 17:23, 9 August 2021

1. Almirall J, Bolíbar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004;125(4):1335-1342. doi:10.1378/chest.125.4.1335

2. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T, CAPNETZ Study Group. CRB-65 predicts death from community-acquired pneumonia. J Intern Med. 2006;260(1):93-101. doi:10.1111/j.1365-2796.2006.01657.x

3. Chalmers JD, Taylor JK, Mandal P, et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis. 2011;53(6):503-511. doi:10.1093/cid/cir463

4. Dinh A, Ropers J, Duran C, et al. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet. 2021;397(10280):1195-1203. doi:10.1016/S0140-6736(21)00313-5

5. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250. doi:10.1056/NEJM199701233360402

6. Först G, Kern WV, Weber N, et al. Clinimetric properties and suitability of selected quality indicators for assessing antibiotic use in hospitalized adults: a multicentre point prevalence study in 24 hospitals in Germany. J Antimicrob Chemother. 2019;74(12):3596-3602. doi:10.1093/jac/dkz364

7. Jensen AV, Faurholt-Jepsen D, Egelund GB, et al. Undiagnosed Diabetes Mellitus in Community-Acquired Pneumonia: A Prospective Cohort Study. Clin Infect Dis. 2017;65(12):2091-2098. doi:10.1093/cid/cix703

8. Kolditz M, Ewig S, Schütte H, et al. Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med. 2015;278(2):193-202. doi:10.1111/joim.12349

9. Laws H-J, Baumann U, Bogdan C, et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsbl. 2020;63(5):588-644. doi:10.1007/s00103-020-03123-w

10. Liapikou A, Ferrer M, Polverino E, et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis. 2009;48(4):377-385. doi:10.1086/596307

11. Moore M, Stuart B, Little P, et al. Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study. Eur Respir J. 2017;50(5):1700434. doi:10.1183/13993003.00434-2017

12. Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest. 2010;138(1):121-129. doi:10.1378/chest.09-2920

13. Nagata N, Nikaido Y, Kido M, Ishibashi T, Sueishi K. Terminal pulmonary infections in patients with lung cancer. Chest. 1993;103(6):1739-1742. doi:10.1378/chest.103.6.1739

14. Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95-107. doi:10.1016/S1473-3099(17)30592-3

15. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984-989. doi:10.1136/thoraxjnl-2015-206780

16. Valvani A, Martin A, Devarajan A, Chandy D. Postobstructive pneumonia in lung cancer. Ann Transl Med. 2019;7(15):357. doi:10.21037/atm.2019.05.26

17. Qualitätsreport 2019. Published online 2019:246.

18. 092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf. Accessed July 9, 2021. https://www.awmf.org/uploads/tx_szleitlinien/092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf

Retrieved from "https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Ambulant_erworbene_Pneumonie/Quellen&oldid=1384"